Scroll To Top
News

Brakes Put to CCR5 Studies

Brakes Put to CCR5 Studies

154_coverx150_10

Brakes Put to CCR5 Studies Although just a year ago entry inhibitors that aim to prevent HIV from latching onto CCR5 receptors on the surface of immune-system cells seemed to be the next big development for treatment, setbacks in clinical trials of the drugs has dampened that enthusiasm. ' GlaxoSmithKline halted human trials of aplaviroc when subjects showed signs of liver damage. ' Schering-Plough halted a study of vicriviroc when data showed it wasn't as effective as hoped. ' Pfizer has reported signs of liver problems with patients in its trial of maraviroc, but it is still unclear whether the problems are related to the medication.

Advocate Channel - The Pride StoreOut / Advocate Magazine - Fellow Travelers & Jamie Lee Curtis

From our Sponsors

Most Popular

Latest Stories

HIV Plus Editors

Editor

Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.

Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.